Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Page 1
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Cytotherapy. 2023 Jul;25(7):763-772. doi: 10.1016/j.jcyt.2023.03.006. Epub 2023 Apr 11.
Cytotherapy. 2023.
PMID: 37055320
Free article.
Here, we present an alternative approach by harnessing the CD38(dim) phenotype occurring during long-term cytokine stimulation of primary NK cells. METHODS: Primary NK cells were expanded from peripheral blood mononuclear cells by long-term IL-2 stimulation. ...
Here, we present an alternative approach by harnessing the CD38(dim) phenotype occurring during long-term cytokine stimulation of pri …
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group.
Flume PA, et al.
Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10.
Lancet Respir Med. 2021.
PMID: 33581080
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability, and efficacy of tezacaftor-ivacaftor in participants aged 12 years or older with cystic fibrosis who were homozygous or heterozygous for t …
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability …
Item in Clipboard
Extracorporeal membrane oxygenation as a bridge to lung transplantation: a long-term study.
Dellgren G, Riise GC, Swärd K, Gilljam M, Rexius H, Liden H, Silverborn M.
Dellgren G, et al. Among authors: gilljam m.
Eur J Cardiothorac Surg. 2015 Jan;47(1):95-100; discussion 100. doi: 10.1093/ejcts/ezu112. Epub 2014 Mar 21.
Eur J Cardiothorac Surg. 2015.
PMID: 24659316
Item in Clipboard
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Björkström NK, Söderdahl G, Cederlund K, Kimby E, Aschan J, Ringdén O, Ljunggren HG, Dilber MS.
Barkholt L, et al. Among authors: gilljam m.
Immunotherapy. 2009 Sep;1(5):753-64. doi: 10.2217/imt.09.47.
Immunotherapy. 2009.
PMID: 20636021
Clinical Trial.
We have recently developed a system that allows expansion of clinical-grade NK and NK-like T cells in large numbers. In this study, the safety of donor-derived long-term ex vivo-expanded human NK and NK-like T cells given as DLIs was investigated as immunotherapy for cance …
We have recently developed a system that allows expansion of clinical-grade NK and NK-like T cells in large numbers. In this study, the safe …
Item in Clipboard
Cite
Cite